查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621513

治療診斷學市場：按產品、應用和最終用戶分類 - 全球預測 2025-2030

Theranostics Market by Product (Product, Services, Software), Application (Bone Metastatis, Cardiovascular Diseases, Lymphoma), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年治療診斷學市場價值為 23.3 億美元，預計到 2024 年將達到 26.7 億美元，複合年成長率為 14.89%，到 2030 年將達到 61.8 億美元。

治療診斷學是治療學和診斷學的組合，代表了個人化醫療的重大進步，旨在提供標靶治療策略，同時透過診斷測試監測治療效果。這兩種方法滿足了針對個別患者情況進行更精確的醫療干預的需求，改善治療結果並最大限度地減少副作用。治療診斷學學應用主要涵蓋腫瘤學、心臟科和神經學，最終用途是醫院、診斷實驗室和專科診所。影響市場成長的關鍵因素包括基因組學和精準醫學的進步、慢性病盛行率的增加以及對個人化治療的需求不斷成長。人工智慧和機器學習的整合存在新的潛在機會，可以提高診斷準確性並簡化治療監測。然而，高昂的開發成本、複雜的監管障礙和有限的報銷框架等限制為市場擴張帶來了挑戰。此外，創新常常受到智慧財產權問題和需要可靠的臨床證據來支持治療診斷方法有效性的阻礙。儘管存在這些挑戰，該市場仍為創新提供了肥沃的土壤，特別是在開發多模態成像劑、增強放射性藥物應用以及探索各種疾病的新型生物標記方面。公司可以透過投資研發合作、專注於具有成本效益的解決方案以及倡導有利的監管政策來促進成長。在技​​術進步和對個人化醫療策略的日益重視的推動下，市場動態正在動態發展。希望利用這一趨勢的公司優先考慮對新技術的敏捷反應，與學術機構建立夥伴關係以擴大研究，並參與策略行銷以改善醫療保健專業人員和患者之間的關係。的認知與教育。這些策略將幫助我們克服挑戰並在這個快速發展的領域中建立強大的地位。

主要市場統計
基準年[2023] 23.3億美元
預計年份 [2024] 26.7億美元
預測年份 [2030] 61.8億美元
複合年成長率（%） 14.89%

市場動態：揭示快速發展的治療診斷學市場的關鍵市場洞察

供需的動態交互作用正在改變治療診斷學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 目標疾病的全球盛行率
    • 個人化醫療與分子生物學的不斷進步
  • 市場限制因素
    • 研發高成本、監理核准複雜
  • 市場機會
    • 治療診斷學中資料分析和機器學習的進一步整合
    • 擴大新生物標記和非侵入性成像技術的開發
  • 市場挑戰
    • 資料隱私和個人化醫療的倫理考量

波特的五力：駕馭治療診斷學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解治療診斷學市場的外部影響

外部宏觀環境因素在塑造治療診斷學市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解治療診斷學市場的競爭格局

對治療診斷學市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣治療診斷學市場供應商績效評估

FPNV定位矩陣是評估治療診斷學市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了治療診斷學市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對治療診斷學市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球目標疾病的盛行率正在增加
      • 個人化醫療與分子生物學的進展
    • 抑制因素
      • 研發成本高、監理核准複雜
    • 機會
      • 治療診斷學中資料分析和機器學習的增強整合
      • 新生物標記和非侵入性成像技術的開發仍在繼續
    • 任務
      • 資料隱私和個人化醫療的倫理考量
  • 市場區隔分析
    • 產品：更多地使用軟體進行資料收集、處理和分析
    • 最終使用者：擴大醫院治療治療診斷學在各種疾病管理的潛力
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章治療診斷學市場：依產品

  • 產品
    • 診斷影像
      • 功能性影像
      • 分子影像
      • 核子造影
    • 體外診斷/生物標記篩檢
      • 螢光原位雜合反應
      • 次世代定序
      • 聚合酵素鏈鎖反應
    • 放射性藥物
      • 氟18
      • 鎵68
      • 碘131
      • 鎦177
      • 鐳223
      • 釤153
      • 鍶89
      • Technetium99
      • 釔90
  • 服務
  • 軟體
    • 影像分析
    • 預測模型

第7章治療診斷學市場：依應用分類

  • 骨轉移
  • 心血管疾病
  • 淋巴瘤
  • 神經內分泌腫瘤
  • 攝護腺癌

第8章治療診斷學市場：依最終使用者分類

  • 癌症護理中心
  • 醫院
  • 研究學術中心
  • 治療診斷學中心

第9章美洲的治療診斷學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太治療診斷學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的治療診斷學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Clarity 的前列腺癌藥物臨床試驗取得最高劑量水平隊列進展
    • BAMF Health 和 GE Healthcare 合作，為治療診斷學的發展提供永續、可擴展的解決方案
    • 加州大學洛杉磯分校健康中心開設治療診斷學中心
  • 戰略分析和建議

公司名單

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMerieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Invicro, LLC
  • Ipsen Pharma
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
  • United Theranostics
Product Code: MRR-61081604A0A5

The Theranostics Market was valued at USD 2.33 billion in 2023, expected to reach USD 2.67 billion in 2024, and is projected to grow at a CAGR of 14.89%, to USD 6.18 billion by 2030.

Theranostics, a portmanteau of therapeutics and diagnostics, represents a significant advancement in personalized medicine, aiming to offer targeted treatment strategies while simultaneously monitoring the therapy's efficacy through diagnostic tests. This dual approach addresses the necessity for more precise medical interventions tailored to individual patient profiles, improving treatment outcomes and minimizing adverse effects. The application of theranostics predominantly spans oncology, cardiology, and neurology, with end-use extending across hospital settings, diagnostic laboratories, and specialty clinics. Key factors influencing market growth include advancements in genomics and precision medicine, increasing prevalence of chronic diseases, and rising demand for personalized treatments. The latest potential opportunities exist in the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and streamline therapeutic monitoring. However, limitations such as high development costs, complex regulatory hurdles, and limited reimbursement frameworks pose challenges to market expansion. Furthermore, technological innovations are often impeded by intellectual property issues and a need for robust clinical evidence to support the efficacy of theranostic approaches. Despite these challenges, the market offers fertile ground for innovation, particularly in developing multimodal imaging agents, enhancing radiopharmaceutical applications, and exploring novel biomarkers for various diseases. Businesses can foster growth by investing in R&D collaborations, focusing on cost-effective solutions, and advocating for favorable regulatory policies. The nature of the theranostics market is dynamic and evolving, driven by technological advancements and an increasing emphasis on personalized care strategies. Companies looking to capitalize on this trend should prioritize agile adaptation to emerging technologies, foster partnerships with academic institutions for research expansion, and engage in strategic marketing to enhance awareness and education about theranostics' benefits among healthcare professionals and patients alike. These strategies can help navigate the challenges and position businesses to ground themselves firmly in this burgeoning field.

KEY MARKET STATISTICS
Base Year [2023] USD 2.33 billion
Estimated Year [2024] USD 2.67 billion
Forecast Year [2030] USD 6.18 billion
CAGR (%) 14.89%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Theranostics Market

The Theranostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of target diseases globally
    • Rising advancements in personalized medicine and molecular biology
  • Market Restraints
    • High costs associated with R&D and the complexity of regulatory approvals
  • Market Opportunities
    • Increasing integration of data analytics and machine learning in theranostics
    • Growing development of novel biomarkers and non-invasive imaging techniques
  • Market Challenges
    • Data privacy and the ethical considerations of personalized medicine

Porter's Five Forces: A Strategic Tool for Navigating the Theranostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Theranostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Theranostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Theranostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Theranostics Market

A detailed market share analysis in the Theranostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Theranostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Theranostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Theranostics Market

A strategic analysis of the Theranostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Theranostics Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Ariceum Therapeutics GmbH, Astellas Pharma Inc., BAMF Health, Bayer AG, bioMerieux SA, Biosynth Ltd., Cardinal Health, Inc., Cerebral Therapeutics, Inc., Clarity Pharmaceuticals, Curasight A/S, Curium Inc., Evergreen Theragnostics, Inc., GE HealthCare Technologies, Inc., Hermes Medical Solutions AB, Icon Group, Indi Molecular, Inc., Integrated Clinical Oncology Network Pty Ltd., Invicro, LLC, Ipsen Pharma, Radiopharm Theranostics Limited, Ratio Therapeutics, Siemens Healthineers AG, SOFIE Co., Telix Pharmaceuticals Limited, and United Theranostics.

Market Segmentation & Coverage

This research report categorizes the Theranostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Product, Services, and Software. The Product is further studied across Diagnostic Imaging, In Vitro Diagnostics/Biomarker Screening, and Radiopharmaceuticals. The Diagnostic Imaging is further studied across Functional Imaging, Molecular Imaging, and Nuclear Imaging. The In Vitro Diagnostics/Biomarker Screening is further studied across Fluorescence In Situ Hybridization, Next-generation Sequencing, and Polymerase Chain Reaction. The Radiopharmaceuticals is further studied across Fluorine-18, Gallium-68, lodine-131, Lutetium-177, Radium-223, Samarium-153, Strontium-89, Technetium-99, and Yttrium-90. The Software is further studied across Imaging Analytics and Predictive Modeling.
  • Based on Application, market is studied across Bone Metastatis, Cardiovascular Diseases, Lymphoma, Neuroendocrine Tumors, and Prostate Cancer.
  • Based on End-User, market is studied across Cancer Care Centers, Hospitals, Research & Academic Centers, and Theranostics Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of target diseases globally
      • 5.1.1.2. Rising advancements in personalized medicine and molecular biology
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and the complexity of regulatory approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing integration of data analytics and machine learning in theranostics
      • 5.1.3.2. Growing development of novel biomarkers and non-invasive imaging techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy and the ethical considerations of personalized medicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising usage of software for data acquisition, processing, and analysis
    • 5.2.2. End-User: Growing potential of theranostics among hospitals for the management of a variety of diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Theranostics Market, by Product

  • 6.1. Introduction
  • 6.2. Product
    • 6.2.1. Diagnostic Imaging
      • 6.2.1.1. Functional Imaging
      • 6.2.1.2. Molecular Imaging
      • 6.2.1.3. Nuclear Imaging
    • 6.2.2. In Vitro Diagnostics/Biomarker Screening
      • 6.2.2.1. Fluorescence In Situ Hybridization
      • 6.2.2.2. Next-generation Sequencing
      • 6.2.2.3. Polymerase Chain Reaction
    • 6.2.3. Radiopharmaceuticals
      • 6.2.3.1. Fluorine-18
      • 6.2.3.2. Gallium-68
      • 6.2.3.3. lodine-131
      • 6.2.3.4. Lutetium-177
      • 6.2.3.5. Radium-223
      • 6.2.3.6. Samarium-153
      • 6.2.3.7. Strontium-89
      • 6.2.3.8. Technetium-99
      • 6.2.3.9. Yttrium-90
  • 6.3. Services
  • 6.4. Software
    • 6.4.1. Imaging Analytics
    • 6.4.2. Predictive Modeling

7. Theranostics Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Metastatis
  • 7.3. Cardiovascular Diseases
  • 7.4. Lymphoma
  • 7.5. Neuroendocrine Tumors
  • 7.6. Prostate Cancer

8. Theranostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Care Centers
  • 8.3. Hospitals
  • 8.4. Research & Academic Centers
  • 8.5. Theranostics Centers

9. Americas Theranostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Theranostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Theranostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
    • 12.3.2. BAMF Health and GE HealthCare Collaborate to Enable Sustainable and Scalable Solutions for Growth in Theranostics
    • 12.3.3. UCLA Health to Open Theranostics Center
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Ariceum Therapeutics GmbH
  • 3. Astellas Pharma Inc.
  • 4. BAMF Health
  • 5. Bayer AG
  • 6. bioMerieux SA
  • 7. Biosynth Ltd.
  • 8. Cardinal Health, Inc.
  • 9. Cerebral Therapeutics, Inc.
  • 10. Clarity Pharmaceuticals
  • 11. Curasight A/S
  • 12. Curium Inc.
  • 13. Evergreen Theragnostics, Inc.
  • 14. GE HealthCare Technologies, Inc.
  • 15. Hermes Medical Solutions AB
  • 16. Icon Group
  • 17. Indi Molecular, Inc.
  • 18. Integrated Clinical Oncology Network Pty Ltd.
  • 19. Invicro, LLC
  • 20. Ipsen Pharma
  • 21. Radiopharm Theranostics Limited
  • 22. Ratio Therapeutics
  • 23. Siemens Healthineers AG
  • 24. SOFIE Co.
  • 25. Telix Pharmaceuticals Limited
  • 26. United Theranostics

LIST OF FIGURES

  • FIGURE 1. THERANOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. THERANOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERANOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERANOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY FUNCTIONAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY LODINE-131, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY SAMARIUM-153, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY STRONTIUM-89, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNETIUM-99, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY BONE METASTATIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY THERANOSTICS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 335. SPAIN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. SWEDEN THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 343. SWEDEN THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 344. SWEDEN THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 345. SWEDEN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SWEDEN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 352. SWITZERLAND THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. SWITZERLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 356. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 357. TURKEY THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 358. TURKEY THERANOSTICS MARKET SIZE, BY IN VITRO DIAGNOSTICS/BIOMARKER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 359. TURKEY THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 360. TURKEY THERANOSTICS MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. TURKEY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 362. TURKEY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES THERANOSTICS